Westwood Holdings Group Inc. Has $29.69 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Westwood Holdings Group Inc. raised its stake in Zoetis Inc. (NYSE:ZTS) by 4.5% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 171,274 shares of the company’s stock after purchasing an additional 7,309 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Zoetis were worth $29,692,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Webster Bank N. A. increased its stake in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Neo Ivy Capital Management acquired a new position in shares of Zoetis during the 4th quarter worth $40,000. LRI Investments LLC acquired a new position in shares of Zoetis during the 1st quarter worth $43,000. Hazlett Burt & Watson Inc. increased its stake in shares of Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the last quarter. Finally, Central Valley Advisors LLC acquired a new position in shares of Zoetis during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $192.64 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market capitalization of $87.90 billion, a price-to-earnings ratio of 37.12, a P/E/G ratio of 2.98 and a beta of 0.88. The company’s fifty day moving average is $184.70 and its two-hundred day moving average is $174.40. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the business posted $1.41 EPS. Equities research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on ZTS. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.